Euronext Paris · Healthcare
Invest in TME Pharma stock from India
Indian and foreign residents can buy TME Pharma (ALTME) shares directly through Paasa.
By Paasa · Updated
TME Pharma at a glance
- Price
- €0.10-€0.00 (0.19%)
- Market cap
- €9.74M
- Day range
- €0.10 – €0.11
- P/E
- -2.96
- Dividend yield
- None
- Volume
- 119.98K
- 1 month
- -29.18%
- 6 months
- +38.42%
- YTD
- +58.59%
- 1 year
- -3.36%
- 5 years
- -99.66%
TME Pharma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €0.0 | €19.0K | €17.0K | €0.0 | €33.0K |
| Gross profit | −€8.0K | −€78.0K | −€127.0K | −€92.0K | −€66.0K |
| Operating income | −€2.9M | −€5.3M | −€5.6M | −€12.0M | −€13.3M |
| Net income | −€3.3M | −€5.7M | −€6.7M | −€15.1M | −€14.5M |
| Earnings per share | −€0.03 | −€0.21 | −€1.34 | −€12.86 | −€21.90 |
| EBITDA | −€2.9M | −€5.2M | −€5.1M | −€11.6M | −€12.9M |
| Total assets | €2.1M | €3.4M | €2.5M | €5.2M | €9.8M |
| Total debt | €2.4M | €56.0K | €1.2M | €4.1M | €2.4M |
| Cash and short-term investments | €2.0M | €3.2M | €2.2M | €4.6M | €9.5M |
| Shareholders' equity | −€1.6M | €1.6M | −€294.0K | −€1.3M | €4.5M |
| Operating cash flow | −€3.4M | −€4.6M | −€5.6M | −€12.1M | −€12.4M |
| Free cash flow | −€3.4M | −€4.7M | −€5.7M | −€12.2M | −€12.4M |
| Capital expenditure | €0.0 | −€16.0K | −€19.0K | −€21.0K | −€14.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Mauna Kea Technologies | ALMKT.PA | €0.13 | €26.13M |
| Valbiotis | ALVAL.PA | €0.71 | €25.20M |
| Biosynex | ALBIO.PA | €0.89 | €16.40M |
| Poxel | POXEL.PA | €0.17 | €9.07M |
| SpineGuard | ALSGD.PA | €0.09 | €8.75M |
| AMA | ALAMA.PA | €0.16 | €8.57M |
| Media Lab | MLLAB.PA | €2.48 | €5.88M |
| Plant Advanced Technologies | ALPAT.PA | €4.24 | €4.83M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in TME Pharma from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search ALTME and buy
Find TME Pharma by name or by its ticker, ALTME, and place your order.
Why invest in TME Pharma from India
What TME Pharma does
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. TME Pharma operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy TME Pharma stock from India?
Yes. Indian residents and NRIs can buy TME Pharma (ALTME) shares directly through Paasa. TME Pharma is listed on Euronext Paris, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
How are TME Pharma dividends taxed for Indian investors?
TME Pharma trades on Euronext Paris but is domiciled in Germany, so any withholding on its dividends follows that country's rules rather than those of France. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell TME Pharma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.